LEI 5493004ZNHN6CAC59L18

GLAXOSMITHKLINE BIOLOGICALS

Group parent: GSK PLC

Awards tracked

14

Value

€14.1M

Countries

BE

Download sample CSV

Contract awards & public grants

Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT) → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2024-12-16

—

Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2021-11-09

—

Innovations to accelerate vaccine development and manufacture → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2021-07-19

—

Preparing for RSV Immunisation and Surveillance in Europe → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2021-05-21

—

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2019-04-30

—

Vaccines and Infectious Diseases in the Ageing PopuLation → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2018-12-10

—

Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2017-10-27

—

Development of Robust and Innovative Vaccine Effectiveness → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2017-08-08

—

REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2016-12-14

—

PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910 → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2016-08-01

—

Vaccine lot to Vaccine lot comparison by consistency testing. → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2016-04-14

—

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2015-02-11

—

Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2014-12-09

€14.1M

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development → GLAXOSMITHKLINE BIOLOGICALS SA

European Commission · BE · Grant · 2014-12-03

—

Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.